CRISPR

CRISPR2-elovl5

ID
ZDB-CRISPR-210513-3
Name
CRISPR2-elovl5
Previous Names
None
Target
Sequence
5' - ACAGGTTATACGGCACCAGC - 3'
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
None
Genome Resources
None
Target Location
Constructs
No data available
Genomic Features
Genomic Feature Affected Genomic Regions
zf3427 elovl5
Expression
Gene expression in Wild Types + CRISPR2-elovl5
No data available
Phenotype
Phenotype resulting from CRISPR2-elovl5
No data available
Phenotype of all Fish created by or utilizing CRISPR2-elovl5
Phenotype Fish Conditions Figures
liver lysophosphatidylethanolamine increased amount, abnormal elovl5zf3427/zf3427 standard conditions Fig. 2 from Sun et al., 2020
liver linoleic acid decreased amount, abnormal elovl5zf3427/zf3427 standard conditions Fig. 1 from Sun et al., 2020
muscle all-cis-8,11,14,17-icosatetraenoic acid decreased amount, abnormal elovl5zf3427/zf3427 standard conditions Fig. 1 from Sun et al., 2020
muscle alpha-linolenic acid decreased amount, abnormal elovl5zf3427/zf3427 standard conditions Fig. 1 from Sun et al., 2020
liver elovl5 expression decreased amount, abnormal elovl5zf3427/zf3427 standard conditions Fig. 3 from Sun et al., 2020
liver phosphatidylethanolamine increased amount, abnormal elovl5zf3427/zf3427 standard conditions Fig. 2 from Sun et al., 2020
liver elovl2 expression increased amount, abnormal elovl5zf3427/zf3427 standard conditions Fig. 3 from Sun et al., 2020
liver alpha-linolenic acid decreased amount, abnormal elovl5zf3427/zf3427 standard conditions Fig. 1 from Sun et al., 2020
liver phosphatidylcholine increased amount, abnormal elovl5zf3427/zf3427 standard conditions Fig. 2 from Sun et al., 2020
liver docosapentaenoate decreased amount, abnormal elovl5zf3427/zf3427 standard conditions Fig. 1 from Sun et al., 2020
muscle docosahexaenoic acid increased amount, abnormal elovl5zf3427/zf3427 standard conditions Fig. 1 from Sun et al., 2020
liver docosahexaenoic acid increased amount, abnormal elovl5zf3427/zf3427 standard conditions Fig. 1 from Sun et al., 2020
liver lysophosphatidylcholine increased amount, abnormal elovl5zf3427/zf3427 standard conditions Fig. 2 from Sun et al., 2020
liver elovl4b expression amount, ameliorated elovl5zf3427/zf3427 standard conditions Fig. 3 from Sun et al., 2020
liver arachidonic acid increased amount, abnormal elovl5zf3427/zf3427 standard conditions Fig. 1 from Sun et al., 2020
liver alpha-linolenic acid normal amount, ameliorated elovl2zf3426/zf3426; elovl5zf3427/zf3427 standard conditions Fig. 1 from Sun et al., 2020
liver elovl2 expression decreased amount, abnormal elovl2zf3426/zf3426; elovl5zf3427/zf3427 standard conditions Fig. 3 from Sun et al., 2020
liver docosahexaenoic acid normal amount, ameliorated elovl2zf3426/zf3426; elovl5zf3427/zf3427 standard conditions Fig. 1 from Sun et al., 2020
liver diglyceride decreased amount, abnormal elovl2zf3426/zf3426; elovl5zf3427/zf3427 standard conditions Fig. 2 from Sun et al., 2020
liver elovl5 expression decreased amount, abnormal elovl2zf3426/zf3426; elovl5zf3427/zf3427 standard conditions Fig. 3 from Sun et al., 2020
liver icosapentaenoate normal amount, ameliorated elovl2zf3426/zf3426; elovl5zf3427/zf3427 standard conditions Fig. 1 from Sun et al., 2020
liver elovl4a expression increased amount, abnormal elovl2zf3426/zf3426; elovl5zf3427/zf3427 standard conditions Fig. 3 from Sun et al., 2020
liver linoleic acid normal amount, ameliorated elovl2zf3426/zf3426; elovl5zf3427/zf3427 standard conditions Fig. 1 from Sun et al., 2020
muscle all-cis-8,11,14,17-icosatetraenoic acid normal amount, ameliorated elovl2zf3426/zf3426; elovl5zf3427/zf3427 standard conditions Fig. 1 from Sun et al., 2020
liver arachidonic acid normal amount, ameliorated elovl2zf3426/zf3426; elovl5zf3427/zf3427 standard conditions Fig. 1 from Sun et al., 2020
muscle alpha-linolenic acid normal amount, ameliorated elovl2zf3426/zf3426; elovl5zf3427/zf3427 standard conditions Fig. 1 from Sun et al., 2020
muscle docosahexaenoic acid normal amount, ameliorated elovl2zf3426/zf3426; elovl5zf3427/zf3427 standard conditions Fig. 1 from Sun et al., 2020
liver monoacylglycerol decreased amount, abnormal elovl2zf3426/zf3426; elovl5zf3427/zf3427 standard conditions Fig. 2 from Sun et al., 2020
muscle icosapentaenoate normal amount, ameliorated elovl2zf3426/zf3426; elovl5zf3427/zf3427 standard conditions Fig. 1 from Sun et al., 2020
liver docosapentaenoate normal amount, ameliorated elovl2zf3426/zf3426; elovl5zf3427/zf3427 standard conditions Fig. 1 from Sun et al., 2020
muscle docosapentaenoate normal amount, ameliorated elovl2zf3426/zf3426; elovl5zf3427/zf3427 standard conditions Fig. 1 from Sun et al., 2020
Citations